Key clinical point: A bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) T cell approach is safe and produced complete responses in the majority of patients with relapsed or refractory non-Hodgkin lymphoma.
Major finding: Eleven of 17 assessable patients had a response to treatment, and of those 11 patients, 9 had complete responses, all of which are ongoing.
Study details: A phase 1 study of 17 patients with relapsed or refractory B-cell non-Hodgkin lymphomas.
Disclosures: Dr. Shah reported disclosures related to Cidara Therapeutics, Exelixis, Geron, Oncosec, Incyte, Jazz Pharmaceuticals, Juno Therapeutics, Kite Pharma, and Miltenyi Biotec.
Shah NN et al. ASCO 2019. Abstract 2510.